Other · developed by Jade Biosciences
JADE101 is a sterile solution given by subcutaneous injection. It is being studied in IgA nephropathy, a form of glomerulonephritis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07902817 | Phase 3 | IgA Nephropathy (IgAN) | Recruiting | JBIO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
IgA Nephropathy (IgAN)
Updated Nov 15, 2026. Something wrong or missing? Report it on the JBIO page.
See JBIO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
JBIO catalysts and pipeline →